Background and objective: Recent studies indicated that non-small cell lung cancer (NSCLC) patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point mutations in codon 12, 13 and 61 of K-ras gene in NSCLC.
Methods: The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues.
Results: No point mutation in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 (0/105).
Conclusion: The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.
背景与目的: 近期研究显示存在K-ras基因突变的非小细胞肺癌（non-small cell lung cancer, NSCLC）患者对表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs）耐药。本研究检测广西地区NSCLC中K-ras基因密码子12、13及61点突变，旨在探讨K-ras基因突变与广西地区NSCLC的关系。
方法: 采用聚合酶链反应-单链构象多态性（polymerase chain reaction-single-strand conformation polymorphism, PCR-SSCP）分析法与PCR-DNA序列分析法联合检测105例新鲜NSCLC手术切除标本和30例癌旁正常肺组织中K-ras基因密码子12、13及61点突变。
结果: 105例NSCLC癌组织及30例癌旁正常肺组织中无1例发生K-ras基因点突变，本研究选取的NSCLC病例组的K-ras基因突变率为0（0/105）。
结论: 广西地区NSCLC中K-ras基因野生型的比例高，提示广西地区NSCLC患者更能从EGFR-TKIs治疗中获益。